Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography

被引:228
作者
Cohen, MS
Arslan, N
Dehdashti, F
Doherty, GM
Lairmore, TC
Brunt, LM
Moley, JF
机构
[1] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA
关键词
D O I
10.1067/msy.2001.118265
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Thyroid tumors often exhibit increased metabolic activity, as evidenced by enhanced glucose uptake on Position emission totnqgraph, (PET) with use of F-18-fluorodeoxyglucose (FDG). The incidence of new thyroid lesions found on routine FDG-PET has not been previously reported. Methods. A retrospective review of all patients who underwent FDG-PET imaging at our institution from June 1, 1996, through March 15, 2001, identified patients with a newly diagnosed thyroid lesion. Thyroid incidentaloma was defined as a thyroid lesion seen initially on FDG-PET in a patient without a history of thyroid disease. Available follow-up data were documented. Results. One hundred and two of 4525 FDG-PET examinations (2.3%) demonstrated thyroid inciden-talomas. Eighty-seven of 102 patients had no thyroid histology because of other malignancies. Fifteen patients had thyroid biopsy: 7 (47%) with thyroid cancer, 6 (40%) with nodular hyperplasia, I with thyroiditis, and 7 with atypical cells of indeterminate origin. The average standardized uptake values were higher for malignant compared with benign lesions. Conclusions. Thyroid incidentaloma identified by FDG-PET occurred with a frequency of 2.3%. Of the thyroid incidentalomas that underwent biopsy, 47% were found to be malignant. Given the risk of malignancy, patients with new thyroid lesions on PET scan should have a tissue diagnosis if it will influence outcome and management. Standardized uptake values may be, helpful in predicting benign versus malignant histology.
引用
收藏
页码:941 / 946
页数:6
相关论文
共 18 条
[1]   POSITRON EMISSION TOMOGRAPHY OF THYROID MASSES [J].
ADLER, LP ;
BLOOM, AD .
THYROID, 1993, 3 (03) :195-200
[2]  
BELL RM, 1986, SURG CLIN N AM, V66, P13
[3]   FDG PET evaluation of mucinous neoplasms: Correlation of FDG uptake with histopathologic features [J].
Berger, KL ;
Nicholson, SA ;
Dehdashti, F ;
Siegel, BA .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2000, 174 (04) :1005-1008
[4]  
BLOOM AD, 1993, SURGERY, V114, P728
[5]  
Feine U, 1996, J NUCL MED, V37, P1468
[6]   Imaging in thyroid cancer [J].
Galloway, RJ ;
Smallridge, RC .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1996, 25 (01) :93-+
[7]  
GRANT CS, 1989, SURGERY, V106, P980
[8]   Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer:: results of a multicentre study [J].
Grünwald, F ;
Kälicke, T ;
Feine, U ;
Lietzenmayer, R ;
Scheidhauer, K ;
Dietlein, M ;
Schober, O ;
Lerch, H ;
Brandt-Mainz, K ;
Burchert, W ;
Hiltermann, G ;
Cremerius, U ;
Biersack, HJ .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (12) :1547-1552
[9]   Nuclear medicine and thyroid cancer [J].
Jana, S ;
Abdel-Dayem, HM ;
Young, I .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (12) :1528-1532
[10]  
KUBOTA K, 1985, J NUCL MED, V26, P37